Theriva Biologics (TOVX) Stock Price, News & Analysis

Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $0.21 to $0.21
• 50-Day Range: $0.21 to $0.31
• 52-Week Range: $0.16 to $0.86
• Volume: 586,362 shs
• Average Volume: 2.46 million shs
• Market Capitalization: $7.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Theriva Biologics Stock Analysis - MarketRank™

Theriva Biologics scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Theriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Theriva Biologics has a consensus price target of $1.00, representing about 376.2% upside from its current price of $0.21.

Amount of Analyst Coverage

Theriva Biologics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Theriva Biologics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.00% of the float of Theriva Biologics has been sold short.

Short Interest Ratio / Days to Cover

Theriva Biologics has a short interest ratio ("days to cover") of 0.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Theriva Biologics has recently increased by 60.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theriva Biologics does not currently pay a dividend.

Dividend Growth

Theriva Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

13 people have searched for TOVX on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Theriva Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.02% of the stock of Theriva Biologics is held by insiders.

Percentage Held by Institutions

6.17% of the stock of Theriva Biologics is held by institutions.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 8/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:TOVX
• CIK: 894158
• Web: therivabio.com
• Phone: (301) 417-4364
• Fax: 301-417-4367
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Theriva Biologics: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +376.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($33.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.74 million
• Net Margins: N/A
• Pretax Margin: -7,153.00%
• Return on Equity: -178.29%
• Return on Assets: -59.96%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 1.63
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 33,740,000
• Free Float: 33,396,000
• Market Cap: $7.09 million
• Optionable: Not Optionable
• Beta: 1.09